ArticleAnnals of nuclear medicine2025
Which factors affect treatment success/prognosis in thyroid cancers with pulmonary metastases and what is/how should be the effective cumulative cure/dose as a current approach; a retrospective study.
Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Radioiodine-Refractory Differentiated Thyroid Carcinoma in Children and Adolescents: A Retrospective Study].Problemy endokrinologii · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur primary objective in this study was to analyse clinical-prognostic factors, to evaluate their effects on response to radioactive iodine therapy (RAIT) and survival in pulmonary metastatic differantiated thyroid cancer. Another aim was to evaluate the treatment cycles/doses to achieve effective treatment at the end of the follow-up.
methods68 patients with pulmonary metastatic differentiated thyroid cancer who met all inclusion criteria were included. Clinical-pathological features and imaging findings of patients were collected and analysed retrospectively.
resultsAdvanced age (p 0.037, OR 1.045), > 2 cm primary tumor (p: 0.009, OR 8), macronodular pulmonary metastases (p: 0.024, OR 3.7) and non-RAI-avidity (p: 0.045, OR 4.5) were independent factors associated with non-response to RAIT. When cumulative RAIT responses in the first 3 cycles were compared, no significant change was observed until the 3rd cycle (up to a cumulative dose of 21.27 GBq). That is, excluding patients who achieved an excellent response in ≤ 2 cycles, it would be appropriate to administer at least 3 cycles (21.27 GBq) to achieve an indeterminate response, which constitutes another pillar of the good prognostic group.
conclusionCollectively, it would be appropriate to consider that response and survival to RAIT decrease in advanced age and in the presence of macronodular pulmonary metastases. In addition to this, it was concluded that at least 3 cycles of RAIT (21.27 GBq) may be appropriate in the determination of treatment-resistant cases, in other words, in the determination of cases in which biochemical-structural incomplete response can be obtained during follow-up.
Indexed as
Identifiers
40388099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.